Why Patients Are Making the Switch from Mounjaro to Wegovy
Online Prescription Process When Switching from Mounjaro to Wegovy
The online prescription process for switching from Mounjaro to Wegovy is designed for patients already familiar with GLP-1 treatments. Our clinical assessment focuses on your current treatment experience, any side effects, and reasons for considering the switch. Licensed UK prescribers evaluate your Mounjaro history to determine appropriate Wegovy starting doses, often beginning at 0.5mg rather than the standard 0.25mg for treatment-naive patients.
Unlike traditional GP appointments that can take weeks to arrange, our online service provides prescriber decisions within 3 working days as standard, or 24 hours with express review. The assessment covers contraindications, current medications, and weight management goals. This streamlined approach recognises that patients switching from Mounjaro to Wegovy already have established treatment patterns and clinical monitoring in place.
Wegovy Pricing and Value When Switching from Mounjaro to Wegovy
Wegovy single pens start at £79.99 for 0.25mg (with FIRST40 for new customers), progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Patients switching from Mounjaro to Wegovy often benefit from our convenience bundles, such as the Progress Duo (0.5mg & 1mg) at £189.99 or the Advance Duo (1mg & 1.7mg) at £269.99. These bundles provide continuity of supply without multiple orders.
Three-pen bundles offer extended supply security, with the Intro Trio (0.25mg, 0.5mg & 1mg) at £299.99 and the Ultimate Stability Trio (three 2.4mg pens) at £649.99 for maintenance patients. Returning customers switching from Mounjaro to Wegovy can use discount code DOSE25 at checkout. All prices include next-day cold-chain delivery from our GPhC-registered pharmacy (#9012378), ensuring temperature-controlled transport essential for semaglutide stability.
Clinical Evidence Supporting Switching from Mounjaro to Wegovy
The STEP trial programme demonstrates Wegovy's efficacy in clinical settings. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, providing additional clinical rationale for some patients switching from Mounjaro to Wegovy.
Individual responses vary between GLP-1 treatments, and some patients may experience different side effect profiles or efficacy when switching from Mounjaro to Wegovy. Clinical monitoring remains important during any transition period, with gradual dose escalation following Wegovy's established protocol regardless of previous Mounjaro dosing.
How Wegovy Works Compared to Your Previous Mounjaro Treatment
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, whereas Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors. Both mechanisms reduce appetite and promote satiety, but the single-pathway approach of Wegovy may suit patients who experienced specific side effects with dual-receptor stimulation. Wegovy works primarily on brain appetite centres, reducing food cravings and helping patients feel satisfied with smaller portions. The once-weekly injection schedule remains the same when switching from Mounjaro to Wegovy, maintaining treatment routine familiarity. Clinical effects typically become apparent within 4-8 weeks of starting Wegovy, similar to your previous Mounjaro experience.
Ordering Process for Patients Switching from Mounjaro to Wegovy
Complete our 3-minute online clinical assessment, indicating your current Mounjaro treatment and reasons for switching. Licensed UK prescribers review applications within 3 working days (or 24 hours with express service), considering your treatment history to recommend appropriate Wegovy starting doses. Once approved, Wegovy ships next-day in temperature-controlled packaging, with tracking provided for delivery confidence. Our pharmacy team coordinates timing to minimise treatment gaps when switching from Mounjaro to Wegovy. Patient support continues throughout your transition, with clinical guidance available for any questions about dose escalation or treatment response.
Storage Advantages When Switching from Mounjaro to Wegovy
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable for 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day limit. This advantage benefits frequent travellers or patients with limited refrigeration access. Wegovy uses Novo Nordisk's FlexTouch pen system, providing consistent injection experience with dose escalation from 0.25mg weekly through to 2.4mg maintenance. Store unopened pens in the refrigerator at 2-8°C, and rotate stock using oldest pens first. The extended room temperature stability makes switching from Mounjaro to Wegovy particularly attractive for patients with active lifestyles requiring treatment portability.
Transition Timeline Considerations When Switching from Mounjaro to Wegovy
Patients switching from Mounjaro to Wegovy typically begin with Wegovy 0.5mg rather than 0.25mg, depending on their previous Mounjaro dose and tolerance. Your prescriber determines the most appropriate starting point based on clinical assessment and treatment history. Some patients may experience a brief adjustment period as their system adapts to single-pathway GLP-1 stimulation versus Mounjaro's dual-receptor approach.
Timing the switch requires coordination to avoid treatment gaps that might affect appetite control and weight management progress. Our prescribers provide specific guidance on when to take your final Mounjaro dose and begin Wegovy treatment. Regular monitoring during the first 8-12 weeks helps optimise your transition experience and identify the most effective Wegovy maintenance dose for your individual response.
Start Your Switch from Mounjaro to Wegovy Today
Begin your transition with confidence through EverydayMeds' expert prescription service, designed specifically for patients switching between GLP-1 treatments. New customers use code FIRST40 and returning customers apply DOSE25 at checkout for our best pricing on genuine Novo Nordisk Wegovy. Our clinical team understands the nuances of switching from Mounjaro to Wegovy, providing personalised support throughout your treatment transition. Visit https://everydaymeds.co.uk/collections/wegovy to complete your clinical assessment and take the next step in your weight management journey. Experience the storage convenience and clinical effectiveness that makes Wegovy the preferred choice for many patients making this important treatment switch.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
